Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib Plus Doxorubicin in Advanced Hepatocellular Carcinoma
NCT01840592Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Apr 2013
- Primary completion
- Apr 2027
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of doxorubicin in hepatocellular carcinoma (HCC), sponsored by Memorial Sloan Kettering Cancer Center. Started Apr 2013; status: active, not recruiting.
02
Drugs
doxorubicin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT01840592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01840592.